Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sichuan Kelun Pharma Buys 12% of Lijun Pharma for $135 Million

publication date: Dec 31, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sichuan Kelun Pharma will spend $135 million to purchase a 12.3% stake in Lijun International Pharma. Both companies are involved in the IV drug market in China, though Lijun’s primary focus is on antibiotics, particularly macrolides. Lijun, which listed on the Hong Kong exchange in 2005, became involved with IV products by buying Shijiazhuang No.4 Pharma in 2007. Kelun will acquire 360 million shares from two of Lijun’s major shareholders. More details....

Stock Symbols: (SHE: 002422) (HK: 2005)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners